Sandborn WJ, et al. - Researchers explored the long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. In this analysis, UNITI-1 (TNF-antagonist failures) and UNITI-2 (conventional therapy failures) subjects (N = 1281) entered IM-UNITI, comprising 397 ustekinumab intravenous induction responders randomised to subcutaneous ustekinumab 90 mg every 12 weeks, every 8 weeks, or placebo and 884 nonrandomised subjects. An aggregate 718 subjects (all treated) entered the long-term extension (298 randomised and 420 not randomised). Findings revealed that subcutaneous ustekinumab maintained clinical response and remission through Week 92. They found no new safety signals.